microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers

Titze‐de‐Almeida, Ricardo; Titze‐de‐Almeida, Simoneide Souza; Ferreira, Gabriel Ginani; Silva, Andrezza Paula Brito; Brandão, Pedro Renato de Paula; Oertel, Wolfgang H.; Schenck, Carlos H.; Rodrigues, Raimundo Nonato

doi:10.1016/j.sleep.2020.12.012

Cited by 11 publications

(7 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A neuromelanin-sensitive MRI study demonstrated decreased signal intensity within the locus coeruleus/subcoerulus, which may involve in maintaining REM muscle atonia, and a corresponding increase in muscle tone during sleep in those individuals with RBD [ 99 ]. Numerous studies have uncovered that PD and RBD share common pathogenesis, such as chronic neural tissue damage and aberrant expressions of microRNAs [ 100 , 101 ]. Molecular imaging also shows that PD with RBD have lower striatal DA transporter activity within the caudate and putamen comparing to PD without RBD, which might imply DA system is also involved in symptomatic progress of RBD in PD [ 102 ].…”

Section: Sleep Disorders and Pharmacological Treatmentsmentioning

confidence: 99%

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Taximaimaiti

Luο

Wang

2021

View full text Add to dashboard Cite

: Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notably decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM) sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.

show abstract

Section: Sleep Disorders and Pharmacological Treatmentsmentioning

confidence: 99%

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Taximaimaiti

Luο

Wang

2021

View full text Add to dashboard Cite

show abstract

“…miR‐214 has the potential to function as a biomarker for prodromal PD, whose expression increases initially and has a propensity to decrease with disease progression 13 . However, miR‐19b was found to decrease in expression at least 5 years before onset of motor symptoms 14 …”

Section: Methods To Assess the Presence And Progression Of Ad And Pdmentioning

confidence: 99%

“…13 However, miR-19b was found to decrease in expression at least 5 years before onset of motor symptoms. 14…”

Section: Biomarkersmentioning

confidence: 99%

A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease

Ghosh,

Sinha,

Sil

2024

Basic Clin Pharma Tox

View full text Add to dashboard Cite

BackgroundsNeurodegenerative diseases (NDDs) such as Alzheimer's (AD) and Parkinson's (PD) are often diagnosed late, impeding effective treatment; therefore, early detection is imperative. Modern methodologies can serve a pivotal role in fulfilling the crucial need for timely detection and intervention in this context.ObjectivesEvaluate early detection's significance and summarize key technologies (biomarkers, neuroimaging, AI/ML, genetics, digital health) for enhanced diagnostic strategies in AD and PD.MethodsThis study employs a focused descriptive review approach, encompassing analysis of peer‐reviewed articles and clinical trials from existing literature, to provide a nuanced exploration of the subject matter.FindingsThis review underscores the efficacy of non‐invasive biomarkers, biosensors and emerging promising technologies for advancing early diagnosis of AD and PD.ConclusionThe landscape of early NDD detection has been reshaped by technology, yet challenges persist, encompassing the domains of validation and ethics. A collaborative effort between medical professionals, researchers and technologists is imperative to effectively address and combat NDDs.

show abstract

“…A number of individual prodromal symptoms, as well as an additional symptom, mild cognitive impairment (MCI), were also shown to be highly predictive of developing PD [ 16 ]. The promising predictive capabilities of these prodromal symptoms have led to the development of many biomarkers and algorithms aiming to identify the early stages of the disease (see reviews [ 17 , 18 , 19 ]). However, current phenotypic biomarkers are unrefined and have varying levels of sensitivity and accuracy [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review

et al. 2022

View full text Add to dashboard Cite

The prodromal phase of Parkinson’s disease (PD) is characterised by many non-motor symptoms, and these have recently been posited to be predictive of later diagnosis. Genetic rodent models can develop non-motor phenotypes, providing tools to identify mechanisms underlying the early development of PD. However, it is not yet clear how reproducible non-motor phenotypes are amongst genetic PD rodent models, whether phenotypes are age-dependent, and the translatability of these phenotypes has yet to be explored. A systematic literature search was conducted on studies using genetic PD rodent models to investigate non-motor phenotypes; cognition, anxiety/depressive-like behaviour, gastrointestinal (GI) function, olfaction, circadian rhythm, cardiovascular and urinary function. In total, 51 genetic models of PD across 150 studies were identified. We found outcomes of most phenotypes were inconclusive due to inadequate studies, assessment at different ages, or variation in experimental and environmental factors. GI dysfunction was the most reproducible phenotype across all genetic rodent models. The mouse model harbouring mutant A53T, and the wild-type hα-syn overexpression (OE) model recapitulated the majority of phenotypes, albeit did not reliably produce concurrent motor deficits and nigral cell loss. Furthermore, animal models displayed different phenotypic profiles, reflecting the distinct genetic risk factors and heterogeneity of disease mechanisms. Currently, the inconsistent phenotypes within rodent models pose a challenge in the translatability and usefulness for further biomechanistic investigations. This review highlights opportunities to improve phenotype reproducibility with an emphasis on phenotypic assay choice and robust experimental design.

show abstract

microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers

Cited by 11 publications

References 92 publications

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease

How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review

Contact Info

Product

Resources

About